JP2008521831A - Ｐｐａｒ活性化合物 - Google Patents

Ｐｐａｒ活性化合物 Download PDF

Info

Publication number
JP2008521831A
JP2008521831A JP2007543613A JP2007543613A JP2008521831A JP 2008521831 A JP2008521831 A JP 2008521831A JP 2007543613 A JP2007543613 A JP 2007543613A JP 2007543613 A JP2007543613 A JP 2007543613A JP 2008521831 A JP2008521831 A JP 2008521831A
Authority
JP
Japan
Prior art keywords
optionally substituted
disease
substituted lower
group
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521831A5 (enExample
Inventor
リン，ジャック
イブラヒム，プラバ，エヌ．
アーティス，ディーン，アール．
ジャン，チャオ
ワン，ウェイルー
シ，シェンフア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexxikon Inc
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of JP2008521831A publication Critical patent/JP2008521831A/ja
Publication of JP2008521831A5 publication Critical patent/JP2008521831A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
JP2007543613A 2004-11-30 2005-11-29 Ｐｐａｒ活性化合物 Pending JP2008521831A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63189304P 2004-11-30 2004-11-30
US71525805P 2005-09-07 2005-09-07
PCT/US2005/043412 WO2006060535A2 (en) 2004-11-30 2005-11-29 Indole derivatives for use as ppar active compounds

Publications (2)

Publication Number Publication Date
JP2008521831A true JP2008521831A (ja) 2008-06-26
JP2008521831A5 JP2008521831A5 (enExample) 2009-01-22

Family

ID=36284449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543613A Pending JP2008521831A (ja) 2004-11-30 2005-11-29 Ｐｐａｒ活性化合物

Country Status (6)

Country Link
US (1) US20060135540A1 (enExample)
EP (1) EP1833787A2 (enExample)
JP (1) JP2008521831A (enExample)
AU (1) AU2005311826A1 (enExample)
CA (1) CA2589896A1 (enExample)
WO (1) WO2006060535A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537103A (ja) * 2019-06-17 2022-08-24 ウーツェーベー ファルマ ゲーエムベーハー 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
US20070249561A1 (en) * 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
GB0715048D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel compounds
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
ES2526966T3 (es) 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
CA2759476C (en) 2009-04-30 2018-10-09 Julie Nicole Hamblin Novel compounds
KR20120097512A (ko) 2009-11-18 2012-09-04 플렉시콘, 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
KR20120112623A (ko) 2009-12-23 2012-10-11 플렉시콘, 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
RU2012136451A (ru) 2010-01-28 2014-03-10 Президент Энд Феллоуз Оф Гарвард Колледж Композиции и способы улучшения активности протеасомы
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP6208122B2 (ja) 2011-05-12 2017-10-04 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子
RU2631487C2 (ru) 2011-05-17 2017-09-22 Плексксикон Инк. Модуляция киназ и показания к её применению
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
US9163021B2 (en) 2012-10-04 2015-10-20 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
PE20151280A1 (es) 2012-12-21 2015-09-12 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
NZ630875A (en) 2013-03-15 2017-12-22 Plexxikon Inc Heterocyclic compounds and uses thereof
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CA2912568A1 (en) 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016044067A1 (en) 2014-09-15 2016-03-24 Plexxikon Inc. Heterocyclic compounds and uses thereof
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA3129180A1 (en) 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
JP6921846B6 (ja) 2016-03-16 2021-09-15 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節およびその適応症のための化合物および方法
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
WO2018175311A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
KR102615829B1 (ko) 2017-07-25 2023-12-20 플렉시콘 인코퍼레이티드 키나제를 조정하는 화합물의 제제
AU2018348241B2 (en) 2017-10-13 2023-01-12 Opna Bio SA Solid forms of a compound for modulating kinases
CN109678784A (zh) * 2017-10-19 2019-04-26 天津师范大学 硫醚化吲哚类化合物及其制备方法
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
CA3176237A1 (en) 2020-04-29 2021-11-04 Jack Lin Synthesis of heterocyclic compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
WO1995026955A1 (en) * 1994-03-30 1995-10-12 Zeria Pharmaceutical Co., Ltd. Indole derivative and medicine containing the same
WO2003064387A2 (en) * 2002-02-01 2003-08-07 F. Hoffman-La Roche Ag Substituted indoles as alpha-1 agonists
US6608059B1 (en) * 2000-06-27 2003-08-19 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2004007451A1 (en) * 2002-07-17 2004-01-22 Astrazeneca Ab Indole-3-sulphur derivatives
WO2004020409A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2005056522A2 (en) * 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
WO2005121141A1 (en) * 2004-06-10 2005-12-22 Oxagen Limited Pyrrolopyridine derivatives and use thereof for treating diseases mediated by prostaglandin d2 (pgd2)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
ATE333275T1 (de) * 1998-02-23 2006-08-15 Univ South Alabama Indole-3-propionsäure, ihre salze und ester als arzneimittel
US6329389B1 (en) * 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
US6331537B1 (en) * 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
BR0212512A (pt) * 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
CA2532403A1 (en) * 2003-07-17 2005-02-03 James Arnold Ppar active compounds
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
US20070232681A1 (en) * 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
WO1995026955A1 (en) * 1994-03-30 1995-10-12 Zeria Pharmaceutical Co., Ltd. Indole derivative and medicine containing the same
US6608059B1 (en) * 2000-06-27 2003-08-19 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2003064387A2 (en) * 2002-02-01 2003-08-07 F. Hoffman-La Roche Ag Substituted indoles as alpha-1 agonists
WO2004007451A1 (en) * 2002-07-17 2004-01-22 Astrazeneca Ab Indole-3-sulphur derivatives
WO2004020409A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2005056522A2 (en) * 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
WO2005121141A1 (en) * 2004-06-10 2005-12-22 Oxagen Limited Pyrrolopyridine derivatives and use thereof for treating diseases mediated by prostaglandin d2 (pgd2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537103A (ja) * 2019-06-17 2022-08-24 ウーツェーベー ファルマ ゲーエムベーハー 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物
JP7631235B2 (ja) 2019-06-17 2025-02-18 ウーツェーベー ファルマ ゲーエムベーハー 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物
US12358875B2 (en) 2019-06-17 2025-07-15 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis

Also Published As

Publication number Publication date
AU2005311826A1 (en) 2006-06-08
WO2006060535A3 (en) 2006-09-14
WO2006060535A2 (en) 2006-06-08
EP1833787A2 (en) 2007-09-19
US20060135540A1 (en) 2006-06-22
CA2589896A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
JP2008521831A (ja) Ｐｐａｒ活性化合物
JP2008521829A (ja) Ｐｐａｒ活性化合物
US20070072904A1 (en) PPAR active compounds
JP2009509932A (ja) Ｐｐａｒ活性化合物
JP2009507846A (ja) Ｐｐａｒ活性化合物
US8053463B2 (en) PPAR active compounds
JP4598278B2 (ja) Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体
JP7224102B2 (ja) 疾患治療用の縮合二環式化合物
KR100762762B1 (ko) Ｐｐａｒ의 조절인자로서의 아릴 화합물 및 신진대사장애의 치료 방법
CN101605775A (zh) 取代的3-苯基-1-(苯基噻吩基)丙-1-酮类以及3-苯基-1-(苯基呋喃基)丙-1-酮类的衍生物、制备以及用途
WO2014207213A1 (en) Novel inhibitors of protein kinase c epsilon signaling
Dhanya et al. Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats
WO2000023442A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
US20070208026A1 (en) N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
WO2020051707A1 (en) Indole-oxadiazole compounds and their therapeutic use
US20070117860A1 (en) Bicyclic indolinesulphonamide derivatives
US20240391928A1 (en) Compositions for the treatment of food and chemical addiction and methods of making and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120731